Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1331Breast Neoplasms 687Carcinoma, Non-Small-Cell Lung 543Neoplasm Metastasis 436Lymphoma 435Leukemia, Myeloid, Acute 432Melanoma 402Prostatic Neoplasms 380Multiple Myeloma 366Lymphoma, Non-Hodgkin 356Ovarian Neoplasms 343Colorectal Neoplasms 333Precursor Cell Lymphoblastic Leukemia-Lymphoma 328Pancreatic Neoplasms 328Leukemia, Lymphocytic, Chronic, B-Cell 323Leukemia 282Lung Neoplasms 275Glioblastoma 267Unspecified Adult Solid Tumor, Protocol Specific 257Recurrence 253Lymphoma, Follicular 248Lymphoma, Large B-Cell, Diffuse 245Brain Neoplasms 232Lymphoma, Mantle-Cell 210Hodgkin Disease 193Carcinoma, Renal Cell 193Head and Neck Neoplasms 192Myelodysplastic Syndromes 187Glioma 172Burkitt Lymphoma 172

Interventions

pembrolizumab 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Completed × Ataxia Telangiectasia × Clear all
NCT04095273 2024-04-02

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

Bayer

Phase 1 Completed
56 enrolled

Ataxia Telangiectasia, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡